Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27346497 | 0.83 | TRPA1 (0.40) | MAPTGAAALDH1A1CHRM1LMNA | |
| SCHEMBL26769169 | 0.83 | ALDH1A1 (0.50) | MAPTSMN1; SMN2GAACRHBPCRHR2 | |
| SCHEMBL27421353 | 0.80 | SMN1; SMN2 (0.41) | MAPTSMN1; SMN2GAACRHBPCRHR2 | |
| SCHEMBL20715472 | 0.79 | ABL1 (0.44) | MAPTSMN1; SMN2GAACRHBPCRHR2 | |
| SCHEMBL526383 | 0.78 | MAPT (0.58) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL1131597 | 0.78 | PTGS1 (0.56) | MAPTALDH1A1CHRM1PDE4ALMNA | |
| SCHEMBL24196455 | 0.78 | FAAH (0.46) | MAPTSMN1; SMN2GAACRHBPCRHR2 | |
| SCHEMBL22680860 | 0.78 | MAPT (0.47) | MAPTSMN1; SMN2GAACRHBPCRHR2 | |
| SCHEMBL14004749 | 0.78 | EPHX1 (0.41) | MAPTSMN1; SMN2GAACRHBPCRHR2 | |
| SCHEMBL8253790 | 0.77 | SMN1; SMN2 (0.45) | MAPTSMN1; SMN2GAACRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS BC INC. (CA) | 2023-08-24 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2021178920-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20210023113-A1 | CONJUGATE OF CYTOTOXIC DRUG AND PRODRUG FORM OF SAID CONJUGATE | SYNDIVIA (FR) | 2021-01-28 | — | — | US | disclosed |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-05-26 | — | — | US | disclosed |
| US-20110237566-A1 | Therapeutic Macrolide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-29 | — | — | US | disclosed |
| US-20110237566-A1 | Therapeutic Macrolide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | MAPT 212/4885SMN1; SMN2 935/4885GAA 998/4885 |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | MAPT 3853/4885SMN1; SMN2 1815/4885GAA 127/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | MAPT 3713/4885SMN1; SMN2 3733/4885GAA 2646/4885 |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | SREBF1, SREBF2, BPTF | MAPT 3915/4885SMN1; SMN2 3141/4885GAA 3621/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | MAPT 3853/4885SMN1; SMN2 1815/4885GAA 127/4885 |
| US-20210023113-A1 | CONJUGATE OF CYTOTOXIC DRUG AND PRODRUG FORM OF SAID CONJUGATE | MTHFD1, UGT1A1, MCL1 | MAPT 2224/4885SMN1; SMN2 1536/4885GAA 301/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | MAPT 4571/4885SMN1; SMN2 3587/4885GAA 2281/4885 |
| US-20110237566-A1 | Therapeutic Macrolide Compounds and Their Use | MALT1, HDAC6, BCL6 | MAPT 4248/4885SMN1; SMN2 2606/4885GAA 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.